Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) ...
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
(RTTNews) - Intellia Therapeutics, Inc. (NTLA) announced that the U.S. FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial evaluating nexiguran ziclumeran (nex-z) in hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results